UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 4, 2026

SERES THERAPEUTICS, INC.
(Exact name of Registrant as Specified in Its Charter)

Delaware	**001-37465**	**27-4326290**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

101 Cambridgepark Drive **Cambridge, MA**	**02140**
(Address of principal executive offices)	**(Zip Code)**

Registrant's telephone number, including area code: (617) 945-9626

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.001 per share	MCRB	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 4, 2026, Seres Therapeutics, Inc. (the "Company") announced its financial results for the quarterly period ended September 30, 2026 and provided operational updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the "Current Report").

Item 7.01 Regulation FD Disclosure.

On November 4, 2026, the Company posted an updated corporate presentation (the "Corporate Presentation") to its website. A copy of the Corporate Presentation is furnished as Exhibit 99.2 to this Current Report and incorporated herein by reference.

The information in Items 2.02 and 7.01 of this Current Report, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Seres Therapeutics, Inc. Press Release issued November 4, 2026
99.2	Seres Therapeutics, Inc. Corporate Presentation dated November 4, 2026
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SERES THERAPEUTICS, INC.

Date: November 4, 2026

By: /s/ Thomas J. DesRosier
Name: Thomas J. DesRosier
Title: Executive Vice President and Chief Legal Officer

SERES THERAPEUTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND ANNOUNCES PLANS FOR ADVANCING DEVELOPMENT OF SER-155 TO PREVENT IMMUNE CHECKPOINT INHIBITOR-RELATED ENTEROCOLITIS (irEC)

Prevention approach aims to keep patients on immune checkpoint inhibitor (ICI) therapy and avoid immunosuppressive irEC treatments, representing an additional broad therapeutic opportunity for SER-155

Seres expects to submit plans for the next irEC study design to the FDA in Q1 2027

Study builds on encouraging investigator-sponsored trial (IST) results, in which 12 of 15 participants (80%) with moderate-to-severe irEC achieved an immunosuppressive-free clinical response of diarrhea following treatment with SER-155

CAMBRIDGE, Mass., November 4, 2026 — Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today reported third quarter 2026 financial results and announced it is progressing plans for a next study evaluating SER-155 for the prevention of immune checkpoint inhibitor-related enterocolitis (irEC) in patients initiating immune checkpoint inhibitor (ICI) cancer therapy, which is expected to include a dose optimization component. The Company anticipates submitting the study design to the FDA in the first quarter of 2027.

The planned study builds on previously announced positive topline results from an investigator-sponsored trial (IST) conducted at Memorial Sloan Kettering Cancer Center (MSK) in patients with moderate-to-severe irEC, in which 80% of participants achieved an immunosuppressive-free clinical response at Day 15, following treatment with SER-155. SER-155 was well tolerated, with no drug-related serious adverse events observed. irEC is a frequent and debilitating adverse reaction associated with widely used ICI cancer therapy that often requires patients to halt life-saving ICI treatment and begin systemic immunosuppressive corticosteroids. irEC is listed as an adverse reaction in the labels of all approved ICIs, including PD-1 inhibitors (Keytruda®, Opdivo®, Zynyz®), PD-L1 inhibitors (Imfinzi®, Bavencio®), CTLA-4 inhibitors (Yervoy®, Imjudo®), and LAG-3 inhibitor (Opdualag) - all of which were therapies received by patients in the IST.

“The irEC IST provided promising evidence that orally administered SER-155 improved epithelial barrier integrity and reduced gastrointestinal inflammation without systemic immunosuppression and was well-tolerated in patients with ICI-induced enterocolitis, “ said Richard Kender, Executive Chairman and Interim Chief Executive Officer of Seres. “Based on those results, and in consultation with key opinion leaders in the field, we determined that developing SER-155 to prevent irEC could address a significant unmet clinical need in patients being treated with ICIs for their cancer. We believe SER-155 may enable ICI patients, of whom there are currently estimated to be approximately 300,000 in the U.S. alone, to remain on their therapy by reducing the occurrence of irEC, which often requires the halting of life-saving cancer treatment. We also think this development approach offers a time and capital efficient path to clinical data and positions SER-155 to potentially address a broad ICI-treated population and

look forward to submitting our planned study design to the FDA in the first quarter of 2027. We are pleased to have two oncology-focused programs for SER-155, one with the goal of preventing irEC, and the other, in allogeneic hematopoietic stem cell transplant (allo-HCT), aimed at reducing the risk of bloodstream infections, a leading cause of mortality in these patients. We continue to seek capital through partnerships and other sources to advance our programs in irEC and in allo-HCT, which is Phase 2 ready, pending funding."

Recent Highlights

SER-155 for the prevention of irEC

- Seres intends to advance SER-155 into a next study evaluating prophylactic oral administration in patients initiating ICI therapy, with a dose optimization component, dependent on funding. The study is being designed in consultation with leading oncologists and irEC experts. As part of the development program, Seres plans to engage with the FDA to discuss study design and potential endpoints, which could include incidence of irEC (all grades), ICI administration, and safety. In addition, Seres looks forward to receiving FDA feedback on plans to optimize prophylactic dosing for the study, which could include a healthy volunteer study component or a dosing lead-in element, the results of which are expected to inform the prophylactic dosing course, before initiating dosing in the broader ICI population. As in the completed IST, the Company anticipates enrolling patients across a wide range of ICI types.
- The prevention approach is designed to reduce incidence of irEC, keep patients on ICI therapy and avoid immunosuppressive irEC treatments. irEC is among the most frequent and severe immune-related adverse reactions in patients receiving ICIs, and affects up to 50% of ICI recipients, with rates varying by ICI type and regimen. Current standard of care for moderate or worse irEC (Grade 2 or above) requires halting life-saving ICI therapy and initiating a systemic immunosuppressive corticosteroid, a biologic, or both, which carry their own toxicities and may compromise the anti-cancer effect of ICI therapy.
- The planned next study builds on encouraging topline results from the open-label IST (NCT06801067) conducted at MSK evaluating SER-155 as a potential treatment in irEC, which Seres reported in July. The study enrolled 15 participants with moderate-to-severe (Grade 2-3) irEC (which represents approximately 25% of all ICI recipients) who were naïve to immunosuppressive therapy; 12 of 15 (80%) of participants treated with SER-155 achieved an immunosuppressive-free clinical response at Day 15, the primary efficacy endpoint, defined as at least a one-grade improvement in diarrhea symptoms without immunosuppressive therapy. Five of 15 participants (33%) achieved immunosuppressive-free complete clinical remission at Day 15. SER-155 was generally well tolerated through Day 43, with no serious adverse events assessed as related to SER-155.
- In the IST, translational biomarkers of gastrointestinal inflammation and mucosal epithelial barrier integrity both improved following SER-155 treatment, with statistically significant reductions by Day 43.
- ICIs represent one of the largest and fastest-growing segments of the oncology market, with the worldwide market valued at well over $50 billion in 2025. In the U.S. alone, it is estimated that 300,000 patients are currently on ICIs, representing a large potential target patient population for SER-155 as a preventative treatment for irEC, and a potential multi-billion-dollar commercial opportunity, as the Company believes that both patients and clinicians will be motivated to adopt a prophylactic approach that could permit patients to remain on their ICI therapy.
- Seres expects to submit the proposed next study design to the FDA in the first quarter of 2027 and engage with the agency thereafter.

- Seres and MSK will present a poster entitled “High Immunosuppressive-Free Response Rate of irEC with SER-155, an Investigational Oral Live Biotherapeutic, as First-Line Therapy, in a Phase 1b Study” at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting in Phoenix, AZ on November 7, 2026. This poster will highlight the promising results of the IST.

Broader pipeline and portfolio

- SER-155 remains Phase 2 ready for the prevention of bloodstream infections in adults undergoing allo-HCT for the treatment of blood cancer, pending funding. SER-155 has received Breakthrough Therapy and Fast Track designations for this indication. Efforts continue to secure funding to advance clinical development for this program.
- On November 3, Seres announced that results from its Phase 1b clinical study of SER-155 in adults undergoing allo-HCT were published in *Nature Medicine,* marking an important milestone for the program and providing recognition of the innovative science being advanced by the Company. The publication reported that SER-155 was generally well tolerated and was associated with a 77% relative risk reduction in BSIs compared with placebo.
- Seres continues to progress development of SER-428, an investigational oral liquid formulation based on a subset of SER-155 strains supported by a grant from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), for dosing in patients who cannot take oral capsules, including critically ill patients who receive nutrition and medications via feeding tube. Seres is designing a Phase 1b open-label trial, in collaboration with Daniel E. Freedberg, M.D., M.S., of Columbia University, and in consultation with CARB-X, to evaluate SER-428 in patients with sepsis who are receiving antibiotics in the Medical Intensive Care Unit (MICU) and are at high risk of additional infection. Further clinical development of SER-428 will be progressed pending funding from grants or other sources.
- The Company continues to advance IND-enabling activities for SER-603, in development for inflammatory bowel disease (IBD), and is engaging potential collaborators to support the clinical advancement of this program as a mono and/or combination therapy.

Corporate Updates

- In October, Seres received the second of the two $12.5 million payments related to the buy-out of potential future VOWST net sales-based milestones from Nestlé Health Science (Nestlé).
- On July 31, Seres entered into an agreement to terminate the lease for its facility at 200 Sidney Street in Cambridge, MA. The early termination materially eliminates the Company’s obligations under the lease as of December 31, 2026, and results in reduced ongoing facility-related cash costs beginning in 2027.

Third Quarter 2026 Financial Results

- Net loss was $16.3 million for the third quarter of 2026, compared to net income of $8.2 million for the same period in 2025. The difference is primarily due to a $25 million installment payment received in the third quarter of 2025 related to the sale of the VOWST business to Nestlé, recognized as a Gain on Sale.
- Research and development expenses were $5.6 million for the third quarter of 2026, compared with $12.6 million for the same period in 2025, reflecting lower facilities costs, transition services agreement (TSA) costs, personnel-related expenses and SER-155 costs driven by lower activities in these areas and cost reduction efforts.

- General and administrative expenses were $5.4 million for the third quarter of 2026, compared with $9.5 million for the same period in 2025, due to lower personnel-related expenses, facilities costs, and IT costs, including those related to IT services provided under the TSA.
- In the third quarter of 2026, the Company recorded a $5.7 million non-cash impairment of assets charge related to the early termination of its lease at 200 Sidney Street.

Cash and Cash Runway

As of September 30, 2026, Seres had $17.5 million in cash and cash equivalents. Based on Seres' currently available cash resources, including the $12.5 million payment received from Nestlé in October, and considering future operating plans, the Company expects to fund operations through the first quarter of 2027. This projection excludes proceeds from any potential future partnerships or other sources of capital.

About Seres Therapeutics

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage biotechnology company developing novel live biotherapeutics products in oncology that address causes of mortality and discontinuation of life-saving cancer treatment, and in inflammatory and immune (I&I) diseases, by modulating host function to protect and improve mucosal epithelial barrier integrity, induce immune homeostasis and tolerance, and prevent the colonization and overgrowth of pathogens in the gastrointestinal (GI) tract. The Company previously led the development and FDA approval of VOWST™, the first orally administered microbiome therapeutic, which was subsequently divested to Nestlé Health Science. SER-155, an investigational cultivated multi-strain biotherapeutic, which has received Breakthrough Therapy and Fast Track designations, is being advanced for the prevention of bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HCT), and is Phase 2 ready, pending receipt of funding. SER-155 is also being developed to prevent immune checkpoint inhibitor-related enterocolitis (irEC), with the aim of enabling patients to continue their ICI cancer therapy and avoid the need for immunosuppressive steroid treatment. Following promising results from an investigator-sponsored trial, Seres plans to submit the design of a study for the prevention of irEC in patients initiating ICI therapy to the FDA. The Company is advancing IND-enabling studies for SER-603, which is in development for inflammatory bowel disease. Mechanistically, Seres' biotherapeutics target the mucosal epithelial barrier-immune interface and are optimized to modulate host function to increase mucosal epithelium integrity, induce immune homeostasis, and prevent the colonization and overgrowth of harmful bacteria in the GI tract. For more information, please visit www.serestherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements about: SER-155 and its intended uses and benefits in irEC; our clinical development plans for SER-155, SER-603 and SER-428, including the design and timing of the next planned study of SER-155 for the prevention of irEC; potential accessibility for patients; planned submissions to and/or engagement with regulatory authorities, including the anticipated timing of FDA feedback; the timing and results of clinical studies and data readouts; the anticipated content and timing of upcoming presentations and conferences; current or future product candidates and their potential impacts and outcomes; the size of potential patient populations and markets and the potential commercial opportunity for SER-155; engagement with potential partners and financing sources; our ability to access capital to advance our programs; IND-enabling activities; our cash runway; the anticipated effects of our lease termination, including expected reductions in facility-related costs; our planned strategic focus; the anticipated timing of any of the foregoing; and other statements that are not historical fact.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: (1) our need for additional funding; (2) our ability to continue as a going concern; (3) we have incurred significant losses, are not currently profitable and may never become profitable; (4) our cost reduction actions may not achieve their intended benefits, including an extended cash runway; (5) our limited operating history; (6) we may not be able to realize the anticipated benefits of the VOWST sale, and may face new challenges as a smaller, less diversified company; (7) we have in the past and may in the future receive notice of the failure to satisfy a continued listing rule from The Nasdaq Stock Market LLC; (8) our novel approach to therapeutic intervention; (9) our reliance on third parties to conduct our clinical trials and manufacture our product candidates; (10) our ability to achieve market acceptance necessary for commercial success; (11) the competition we will face; (12) our ability to protect our intellectual property; (13) impact of our recent management transitions and appointments and our ability to retain key personnel; and (14) disruptions at the FDA or other government agencies. These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026, to be filed with the Securities and Exchange Commission (SEC), as well as our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

SERES THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited, in thousands, except share and per share data)

	September 30, 2026	December 31, 2025
Assets		
Current assets:		
Cash and cash equivalents	$ 17,528	$ 45,766
Accounts receivable due from SPN - related party	12,500	360
Accounts receivable	183	157
Prepaid expenses and other current assets	4,212	3,093
Total current assets	34,423	49,376
Property and equipment, net	2,999	7,635
Operating lease assets	27,662	72,483
Restricted cash	773	8,668
Other non-current assets	31	31
Total assets	$ 65,888	$ 138,193
Liabilities and Stockholders' Equity		
Current liabilities:		
Accounts payable	$ 1,461	$ 1,682
Accrued expenses and other current liabilities	3,504	3,972
Accrued liabilities due to SPN - related party	3,278	3,278
Operating lease liabilities	12,650	10,390
Total current liabilities	20,893	19,322
Operating lease liabilities, net of current portion	23,122	72,576
Other long-term liabilities	514	2,077
Total liabilities	44,529	93,975
Commitments and contingencies (Note 9)		
Stockholders' equity:		
Preferred stock, $0.001 par value; 10,000,000 shares authorized at September 30, 2026 and December 31, 2025; no shares issued and outstanding at September 30, 2026 and December 31, 2025	—	—
Common stock, $0.001 par value; 360,000,000 shares authorized at September 30, 2026 and December 31, 2025; 10,049,501 and 9,556,466 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively	10	10
Additional paid-in capital	1,025,370	1,016,611
Accumulated deficit	(1,004,021)	(972,403)
Total stockholders' equity	21,359	44,218
Total liabilities and stockholders' equity	$ 65,888	$ 138,193

SERES THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME
(unaudited, in thousands, except share and per share data)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2026	2025	2026	2025
Revenue:				
Grant revenue	593	351	1,687	351
Total revenue	593	351	1,687	351
Operating expenses:				
Research and development expenses	5,592	12,616	27,928	37,376
General and administrative expenses	5,448	9,476	20,579	31,617
Impairment of long-lived assets	5,705	—	11,512	—
Manufacturing services	—	736	—	5,952
Total operating expenses	16,745	22,828	60,019	74,945
Loss from operations	(16,152)	(22,477)	(58,332)	(74,594)
Other income (expense):				
Gain on sale of VOWST Business	—	27,222	25,000	79,588
Interest income	146	618	652	1,782
Other income (expense) (1)	(280)	2,841	1,062	14,255
Total other income (expense), net	(134)	30,681	26,714	95,625
Net (loss) income and comprehensive (loss) income	$ (16,286)	$ 8,204	$ (31,618)	$ 21,031
Net (loss) income per share attributable to common stockholders - basic	$ (1.63)	$ 0.94	$ (3.24)	$ 2.41
Net (loss) income per share attributable to common stockholders - diluted	$ (1.63)	$ 0.94	$ (3.24)	$ 2.40
Weighted average common shares outstanding - basic	9,982,031	8,758,692	9,764,763	8,735,418
Weighted average common shares outstanding - diluted	9,982,031	8,771,519	9,764,763	8,744,797

[1] Includes $0, $0, $2,028, and $11,827 for the three and nine months ended September 30, 2026 and 2025 related to reimbursement received from SPN (related party) for transition services provided by the Company.

Investor and Media Contact:

IR@serestherapeutics.com

Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com

Exhibit 99.2

SERES THERAPEUTICS

Company Overview


Harnessing the therapeutic potential of microbes to advance the treatment of cancer and inflammatory & immune diseases

2026Q3









Disclaimers

Forward Looking Statements

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this communication that do not relate to matters of historical fact should be considered forward-looking statements, including statements about: the design, timing and results of our current or planned preclinical and clinical trials, studies and data readouts; current or future products or product candidates and their potential benefits; our clinical development plans; communications with, feedback from, or submissions to the FDA; future product candidates; our ability to secure a strategic partnership and or funding sources; the advancement of IND-enabling activities; our drug candidates and their potential impacts and outcomes, including the potential market and commercial opportunity for SER-155, if approved; operating plans and our future cash runway; our planned strategic focus; the anticipated timing of any of the foregoing; and other statements that are not historical fact.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements, including, but not limited to, the following: (1) our need for additional funding; (2) our ability to continue as a going concern; (3) we have incurred significant losses, are not currently profitable and may never become profitable; (4) our cost reduction actions may not achieve their intended benefits, including an extended cash runway; (5) our limited operating history; (6) we may not be able to realize the anticipated benefits of the VOWST sale, and may face new challenges as a smaller, less diversified company; (7) we have in the past and may in the future receive notice of the failure to satisfy a continued listing rule from The Nasdaq Stock Market LLC; (8) our novel approach to therapeutic intervention; (9) our reliance on third parties to conduct our clinical trials and manufacture our product candidates; (10) our ability to achieve market acceptance necessary for commercial success; (11) the competition we will face; (12) our ability to protect our intellectual property; and (13) the impact of our recent management transitions and appointments and our ability to retain key personnel; and (14) disruptions at the FDA or other government agencies. These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026, to be filed with the Securities and Exchange Commission (SEC) on November 4, 2026, as well as our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this communication. Any such forward-looking statements represent management's estimates as of the date of this communication. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this communication.

SERES THERAPEUTICS

Seres has pioneered a new drug modality and accessed the vast functional and therapeutic potential of microbes to treat and prevent disease

2023 VOWST™ FDA approval and launch*

Track-record of realizing ambitious, impactful therapeutic goals: First company to go from novel concept through clinical development to FDA approval/commercialization of **oral biotherapeutic** (VOWST™)

Achieved **two Breakthrough Therapy Designations** (VOWST & SER-155)

Clinically demonstrated biotherapeutics **can target the mucosal epithelial barrier-immune interface** and achieve **placebo-like safety profile** across multiple patient populations

AI-enabled MbTx® Platform that interrogates microbe-host functional interactions and their links to disease and patient heterogeneity with **demonstrated clinical translation of targeted mechanisms of action**


- Two **programs in oncology** that address causes of mortality and discontinuation of life-saving treatment in cancer patients
- Focused on addressing unmet medical needs in **oncology and inflammatory & immune disease** with broad potential based on uniquely targeting the mucosal epithelial barrier-immune interface
- Novel drug modality with potential to target upstream drivers of inflammatory responses and challenges of antimicrobial resistance infections

*VOWST US & Global rights sold to NHSc in 2024

SERES THERAPEUTICS™

Harnessing the therapeutic potential of microbes with live biotherapeutics


Microbe-human functional interactions co-evolved for millions of years and are integral to the body's immune & metabolic function



Consortia of bacteria that are optimized to produce therapeutically active metabolites that target multiple disease-relevant pathways



Formulated for oral administration; manufactured from master cell banks



Clinical translation achieved on targeting mucosal epithelial barrier-immune interface drivers of disease

Well-tolerated safety profile across multiple patient populations reducing clinical development risk

SERES THERAPEUTICS

Addressing critical, unmet medical needs in oncology and inflammatory & immune diseases that are linked to disrupted mucosal epithelial barrier and immunity

SER-155, Breakthrough Therapy
Phase 2 Ready

Hematopoietic allogeneic stem cell transplant (allo-HCT)

- Patients are severely immune compromised with high-risk of bloodstream infections (BSIs) post stem cell transplant
- BSIs, many that are antimicrobial resistant infections, are the leading cause of death in first 100 days post stem cell transplant in adults; ~7.5% mortality rate from BSI.
- Recent increased use of post-transplant cyclophosphamide for GvHD is increasing BSI risk by ~2.4-fold

SER-155
FDA engagement planned for next study

Immune checkpoint inhibitor related enterocolitis (irEC)

- Activation of immune cells by immune checkpoint inhibitor therapy (ICI) to attack cancer tumors can damage healthy tissues causing severe diarrhea and colitis (irEC) and hospitalization
- Up to 50% of ICI patients can experience irEC depending on ICI type/regimen; Moderate-to-severe (Grade 2-3) irEC occurs in ~25% of ICI patients and Grade 2 or higher requires treatment and disrupts life-saving cancer treatment
- Current immunosuppressive treatment options are inadequate with negative side effects

SER-603
IND-enabling Studies underway

Inflammatory Bowel Disease (IBD)

- Current treatments have an efficacy ceiling due to non-response or poor durability of response
- Safety profile of immune suppressive treatments limit the potential for combining advanced therapies to improve efficacy
- Available therapies do not target upstream drivers of disease
- Patient heterogeneity is a core challenge and key reason many drugs have limited efficacy and durability


SERES THERAPEUTICS

SER-155 Allo-HCT: Ph1b demonstrated 77% relative risk reduction in bloodstream infections (BSI) and well-tolerated

FDA Breakthrough Therapy

Clinical Efficacy & Safety

Primary endpoint: relative risk reduction in BSI (placebo-controlled, mITT n=34)



- Observed reduction in febrile neutropenia
- Observed significant reductions ($p \leq 0.05$) in healthcare utilization, days of antibiotics use, and hospitalization
- Efficacy, safety & drug pharmacology reported in Ponce et al. 2026. *Nature Medicine*

Well-tolerated; No Drug-related Serious Adverse Events (SAEs) identified

Opportunity

Prevent bloodstream & antimicrobial resistant (AMR) infections linked to mortality in allo-HCT recipients and other blood cancer patients

- Infectious disease and hematology-oncology physicians rank BSIs in allo-HCT as a 6 on 7-point scale of risk concern
- Allo-HCT is a costly procedure (~$400K US year per patient); incremental costs of infections are significant (incremental ~$242K/patient).
- ~40K allo-HCT transplants worldwide annually with indication expansion potential in additional cancer patients at high risk of infection (~560K)

- Phase 2 Ready -
Agreement with FDA on study design; interim analysis may enable expedited development path

SERES THERAPEUTICS

SER-155 irEC: Investigator sponsored Phase 1b study demonstrated 80% immunosuppressive-free clinical response and well-tolerated

Clinical Efficacy & Safety

Primary endpoint: Immunosuppressive-free clinical response at Day 15 (open label n=15)



80% of all participants *achieved* Response (diarrhea decrease by one or more Grades)

33% of all participants *achieved* Remission (Grade 0; no diarrhea)

Grade 0: 5 of 12 participants
Grade 1: 7 of 12 participants

Well-tolerated; No Drug-related Serious Adverse Events (SAEs) identified

Opportunity

Enable patients receiving immune checkpoint inhibitors to remain on life-saving cancer treatment

- Immune checkpoint inhibitors revolutionized cancer treatment and represent an ~$50B global market; an estimated 300,000 and ~3M patients are projected to be treated in US and worldwide in 2026
- Immune checkpoint inhibitors cause irEC in up to 50% of patients depending on ICI type/regimen; moderate-to-severe (Grade 2-3) irEC occurs in ~25% of ICI patients and Grade 2 or higher disrupts life-saving cancer treatment and requires treatment with immune suppressive drugs that have additional side-effects. Grades 4-5 are life-threatening


- FDA engagement planned for next study –
Positive engagement with KOLs on study design

SERES THERAPEUTICS

SER-603 IBD: Improves response to IBD drugs in preclinical models and Seres unique translational biomarkers can predict response to advanced biologics

Preclinical

SER-603 targets unique upstream mechanisms of action to treat inflammation with potential as mono- or combo-therapy to address efficacy ceiling



- Achieve greater efficacy using combination therapy of SER-603 + biologic (anti-TNF-α)
- SER-603 can also significantly reduce inflammation as monotherapy (data not shown)

Opportunity

Expand therapeutic and commercial potential for existing IBD therapies by increasing response rates and expanding durability of response

- Convert partial and non-responding inflammatory bowel disease patients to clinical responders
- Address current biologics efficacy ceiling by targeting upstream drivers of disease not currently accessed and without immunosuppression
- Seres identified & confirmed novel, microbial-linked biomarkers that can predict response to current IBD therapies to address challenge of patient heterogeneity
- Potential in mild-to-moderate and moderate-to-severe patients; >700K (UC & Crohn's) and >900K (UC) in the US respectively


- IND enabling studies underway -

SERES THERAPEUTICS

Seres has clinically translated targeting the mucosal epithelial barrier-immune interface

Gastrointestinal Mucosal Epithelial Barrier-Immune Interface

Disruption leads to translocation of pro-inflammatory molecules and microbes that drive aberrant host immune responses causing inflammatory and immune disease, and infection



Inhibit Inflammatory Microbes & Pathogens

Intestinal Mucosal Epithelial Barrier Integrity

Immune Function and Regulation

Seres biotherapeutics target multiple upstream drivers of mucosal epithelial barrier disruption, inflammation and infection without being immunosuppressive

Current therapies only target downstream via immune suppression

SERES THERAPEUTICS

Seres has full stack platform capabilities & experience in novel biotherapeutic modality that has delivered two Breakthrough Therapies and a drug licensure

MbTx® Platform

AI and ML enabled engine that interrogates microbe-host functional interactions and their links to disease and patient heterogeneity with demonstrated clinical translation

Field-leading Microbiome biomarker & drug target identification

---

strains, metabolites/peptides, genes

Efficient Lead Candidate Design, Screening, Optimization


---

expansive strain library with screening & models adapted for novel drug modality

Demonstrated Clinical Translation & Identification of Patient Subpopulations

---

novel drug modality PK/PD/MoAs; biomarkers for patient heterogeneity; receipt of breakthrough designation



Field-leading Manufacturing & Clinical Development

Successfully advanced multiple biotherapeutics into early- and late-stage clinical trials with an FDA licensure achieved

Demonstrated Novel Therapeutic GMP Manufacturing & Quality

---

spans broad biological breadth with demonstrated commercial success and clean regulatory inspection history

Proven Regulatory Expertise

Pioneered regulatory path for novel drug modality with FDA approval

Exceptional Clinical Trial Execution

Proprietary know-how on trial design, enrollment in challenging populations, drug pharmacology & sample collection

SERES THERAPEUTICS™

Focused strategy to advance novel biotherapeutics and deliver shareholder value

Pipeline of novel live biotherapeutics in areas each with multibillion commercial potential

- Two **programs in oncology** that address causes of mortality or discontinuation of life-saving treatment in cancer patients
  - **Bloodstream and antimicrobial resistant infections in stem cell transplant (allo-HCT) and blood cancers**
    Partner Breakthrough Therapy, Phase 2 ready SER-155 program and achieve study interim analysis (~12 months from FPI) to enable expedited path to licensure discussion with regulators
  - **Immune checkpoint inhibitor-related enterocolitis (irEC)**
    Develop prophylaxis clinical protocol and engage FDA in 2027Q1
- Position promising preclinical biotherapeutic programs that target mucosal epithelial barrier-immune interface associated inflammatory and immune diseases and antimicrobial resistant infections for future clinical development

---

Capital Strategy & Financial position

- Seres efforts ongoing to seek partnerships and funding to support continued development toward meaningful clinical milestones across pipeline assets
- Recent balance sheet strengthening actions: Nestlé Health Science buy-out of potential future VOWST™ net sales-based milestones ($25 million received) and restructuring of two leases, including early terminations, to materially reduce leased space and ongoing annual facilities cash costs
- Cash runway projected through Q1 2027

SERES THERAPEUTICS™

Pipeline: Seres biotherapeutics target mucosal epithelial barrier-immune associated inflammatory diseases and infection leveraging years of clinical progress and data

Preclinical	Ph1	Ph2	Ph3	Enabling Collaborators
SER-155 *for preventing pathogen translocation and resulting bloodstream and AMR infections in allo-HCT*		**Breakthrough Therapy Designation; Phase 2 ready;** *Ph1b demonstrated well-tolerated and 77% relative risk reduction in blood stream infections with clinical translation of mucosal barrier integrity MoA*		Memorial Sloan Kettering Cancer Center; CARB-X
SER-155 *for immune checkpoint related enterocolitis (irEC)*		**Topline Readout for Investigator sponsored Phase 1b in 2026Q2;** *Ph1b demonstrated 80% immunosuppressive-free clinical response; potential to address one of most significant immune checkpoint inhibitor AEs; Prophylactic trial design in progress*		Memorial Sloan Kettering Cancer Center
SER-603 *for inflammatory bowel disease (IBD)*	**IND-enabling studies underway;** *Potential to target upstream disease pathways that current therapies cannot access and to predict response to advanced biologics*			Crohn's & Colitis Foundation
SER-428 *for reducing AMR infections in ICU*	**IND-enabling studies underway;** *Novel liquid formulation suitable for targeting bloodstream and antimicrobial resistant infections in patients unable to swallow capsules (e.g., intubated patients in ICU)*			CARB-X
SER-147 *for reducing spontaneous bacterial peritonitis*	**Lead screening & drug candidate nomination;** *Potential to address multiple complications of decompensation in cirrhosis patients*			

AMR = Antimicrobial resistant infections
ICU = Intensive care unit
AE = Adverse event


SERES THERAPEUTICS

SER-155

Allogeneic hematopoietic stem cell transplant (allo-HCT)

Prevention epithelial barrier damage and resulting bloodstream infections (BSI) that can lead to mortality

Breakthrough Therapy Designation & Phase 2 Ready



SERES THERAPEUTICS

Translocation of pathogens are a significant problem in allogeneic hematopoietic cell transplant patients (allo-HCT) and leading cause of mortality

Infection is the leading cause of death in first 100 days post-HCT, and recent increased use of post-transplant cyclophosphamide (PTCy) for GvHD is increasing bloodstream (BSI) risk by ~2.5-fold

- **HCT conditioning chemotherapy and frequent antibiotic use leads to gastrointestinal (GI) pathogen domination and compromised mucosal epithelial barrier that can lead to translocation of bacteria to bloodstream**
- **Allo-HCT patients are severely immunocompromised with high-risk of bloodstream infections (BSIs) post-HCT, especially HCT Day 0-30**
- **Infection is the leading cause of death in first 100 days post-HCT in adults, ~7.5% mortality rate from BSI; Efficacy of prophylactic antibacterials to prevent BSI is increasingly limited by antimicrobial resistance**
- **Infectious disease and hematology-oncology physicians are highly concerned about BSIs in allo-HCT patients; rank BSIs as 6 on 7-point scale* of risk concern and indicate effective prophylaxis is a major unmet need**



*Seres primary market research 2024 Trinity Life Sciences survey of hematologists and infectious disease specialists

SERES THERAPEUTICS™

A significant unmet need exists to prevent bloodstream (BSI) and antimicrobial resistant (AMR) infections in immunocompromised patients

- **Address conditioning chemotherapy and prophylactic antibiotic use damage to gastrointestinal microbiome and mucosal epithelial barrier that lead to infections**
- **Prevent infections while highly immunocompromised transplant patients recover immune system function**
- **Reduce prophylactic antibiotics use that are increasing the risk of antimicrobial resistant infections**

SER-155, an investigational live biotherapeutic, has potential to prevent BSI and associated mortality, and to reduce antibiotic use that leads to antimicrobial resistance (AMR)

--

Potential to address both the causes and antibiotic treatment limitations of bloodstream infections

SERES THERAPEUTICS™

Top-Line Results Summary: SER-155 prevented bloodstream infections and protected and repaired the mucosal epithelail barrier integrity

Phase 1b Randomized placebo-controlled 1:1 Cohort 2 (n=34 mITT); open-label Cohort 1 (n=11 mITT) established safety and PK/PD

Efficacy	**77% relative risk reduction in bloodstream infections (BSI) compared to placebo (p<0.05; primary endpoint)**
Safety	**Well-tolerated with No Drug related Serious Adverse Events (SAEs) identified**
Drug Pharmacology	**Observed clinical translation on reduction in pathogen burden in gastrointestinal tract and protection and repair of mucosal epithelial barrier**

SER-155 has the potential to become a critical component of care of immunocompromised patients

—


Prevent infections that lead to medical complications and mortality

SERES THERAPEUTICS

Bloodstream infections (BSIs) are a leading cause of death post-transplant and are increasing in incidence with uptake of post-transplant cyclophosphamide (PTCy)

Incidence

- **BSI risk increasing** due to recent adoption of post-transplant cyclophosphamide (PTCy) for GvHD prophylaxis
- BSI prevalence high **despite standard of care use of antibacterial prophylaxis**
- Majority of BSIs in first 30 days post-HSCT are seeded from the gastrointestinal tract
- 60-90% febrile neutropenia incidence



Impact


- Infection is **leading cause of death** in first 100 days post-HSCT for adults
- **~7.5% mortality rate** from bloodstream infections
- Complications including infection associated with longer hospital stay and ICU utilization, driving **substantial cost increase**

Sources: Gill et al, Microorganisms 2023; Sava et al, Bone Marrow Transplantation 2022; Carreira et al, Transplant Cell Ther 2022; Tamburini et al, Nature Med, 2018; Göldel, et al, Blood, 2024; Rearigh et al, Ann Hematol, 2020; Song et al, Infect Drug Resist 2023; Bolaños-Meade J et al, NEJM 2023; Salas et al, Transplant Cell Ther 2024; Nesher et al, Principles and Practice of Transplant Infectious Diseases, 2019 CIBMTR 2023 US summary slides; Perales et al Biol Blood Marrow Transplant 2017; Taplitz et al, J Clin Oncol 2018; Bolon et al, Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides, 2022. http://www.cibmtr.org; Poutsiaka, et al D., Bone Marrow Transplant, 2007

SERES THERAPEUTICS

SER-155 Phase 1b in allo-HCT: Reduction in bloodstream infections, healthcare and antibiotic utilization, with placebo-like safety


Significant reduction ($p < 0.05$) in bloodstream infection (BSI) incidence (HCT Day 0-30)




*All participants received prophylactic antibiotics, intended to prevent BSI, as standard of care. Prophylactic antibiotics were highly associated with BSI bacteria exhibiting AMR. Resistance to multiple antibacterial classes was observed only in BSI bacteria with placebo treatment.


Two placebo-treated participants with BSIs had fatal outcomes from the BSI.

Significant reduction ($p \leq 0.05$) in healthcare utilization: days of antibiotics and hospitalization





Numerical reduction ($p > 0.05$) in febrile neutropenia (FN) incidence




FN and BSI are major drivers of systemic treatment antibiotic use, and thus potential drivers of antimicrobial resistance (AMR)

Efficacy, safety & drug pharmacology reported in Ponce et al. 2026. *Nature Medicine*

SERES THERAPEUTICS


SER-155 Phase 1b in allo-HCT: Clinical translation on all drug mechanisms of action further support observed efficacy results

Rapid protection of gastrointestinal mucosal epithelial barrier integrity




SER-155 prevents the loss of GI epithelial barrier integrity due to HCT conditioning chemotherapy; Significantly lower ($p \leq 0.05$) fecal albumin in SER-155 treated versus placebo post treatment

Substantial reduction in pathogen domination in the GI microbiome



GI pathogen domination is associated with bloodstream infections and mortality in allo-HCT.

Improved immune homeostasis reflected in plasma cytokine profile



SER-155 reduced multiple pro-inflammatory cytokines associated with the HCT procedures.

Efficacy, safety & drug pharmacology reported in Ponce et al. 2026. *Nature Medicine*

SERES THERAPEUTICS

SER-155 Safety: Generally well-tolerated with no treatment-related severe adverse events (SAEs)

Treatment-Emergent Adverse Events (TEAEs)



- All but one subject in the placebo arm experienced at least 1 TEAE
- Most common for SER-155 treated subjects (≥50% and with a delta ≥5% more than placebo): diarrhea (86% vs. 74% placebo), nausea (62% vs. 53% placebo)
- 1/40 (3%) subject experienced a TEAE leading to treatment discontinuation (active = 0; placebo = 1)
- 4/40 (10%) subjects experienced a TEAE leading to study discontinuation (active = 2; placebo = 2)

Serious Adverse Events (SAEs)



- 19/40 (48%) subjects experienced an SAE: 11/21 (52%) SER-155-treated subjects vs. 8/19 (42%) placebo-treated subjects; none considered related to SER-155 (no SUSARs)
  - Most common SAE SOC: infections & infestations (24% active vs. 37% placebo)
  - 3 deaths prior to Day 100 (active = 1; placebo = 2), 1 death after Day 100 (active), none considered related to SER-155

Adverse Events of Special Interest (AESIs)



- AESIs (bloodstream infections, GI infection, invasive infection): 14/40 (35%) subjects
- Rates of AESIs were lower in SER-155 arm vs placebo arm (29% vs 42% respectively)
- No SER-155 species were identified in culture from any subject

Results above for Cohort 2 Safety Population

SERES THERAPEUTICS™

SER-155 BSI Path Forward: SER-155 is Phase 2 ready in allo-HCT and design provides opportunity for adjacent indication expansion

Phase 2 Allo-HCT

- Received Fast Track and Breakthrough Designation
- FDA in agreement with Phase 2 study design (submitted to FDA January 2026)
- FDA open to expedited path to engage and start Phase 3 if the interim analysis shows overwhelming efficacy
- Finalized Protocol Clinical Site infrastructure in place and key manufacturing steps advanced

Expansion: Auto-HCT, CAR-T & Cancer neutropenia

- Allo-HCT bloodstream and antimicrobial resistant infections has strong biological adjacencies to auto-HCT, CAR-T, and blood cancers (e.g., AML & cancer neutropenia)
- Allo-HCT Phase 2 interim analysis data could trigger advancement in expansion indications
  - Auto-HCT has similar treatment and conditioning regimens to allo-HCT; potential for for one pivotal registrational study in auto- triggered by allo-HCT interim analysis and initial BLA approval for both allo- and auto-HCT together may be possible
  - Febrile neutropenia and BSI data at allo-HCT Phase 2 interim analysis could accelerate clinical evaluation in CAR-T & Cancer neutropenia/AML

SERES THERAPEUTICS

SER-155 in allo-HCT commercial opportunity is meaningful and has indication expansion potential (~15x addressable population) creating multi-billion dollar opportunity

	Allo-HCT	Autologous HCT	CAR-T	Cancer Neutropenia / Broader leukemia & lymphoma population*
WW annual diagnoses or transplants	~40,000	~60,000	~20,000	~500,000
US annual diagnoses or transplants	~9,300	~13,500	~10,000	~87,000 initial focus
Unmet needs addressed by SER-155	Prevent mortality and cost of post-transplant infections	Prevent mortality and costs of post-transplant infections	Reduce life-threatening infections, CRS, ICANS & Enhance CAR-T efficacy	Reduce morbidity, mortality, and costs of infections & FN from chemotherapy

*Includes acute myeloid leukemia, multiple myeloma, and aggressive B cell non-Hodgkin lymphomas (diffuse large B-cell lymphoma, mantle cell, Burkitt's lymphoma) at risk
Sources: WBMT Global Transplant Activity Data, CIBMTR 2024 and 2025 annual reports, US NCI SEER Cancer Stat Facts 2026, National Pharmaceutical Council-2025 CAR-T Cell Therapy Transformation Report; Thandra et al 2021 report of WHO data, Niederwieser et al Haematologica 2022; Greco et al 2026 the 2024 EMBT activity report, Bone Marrow Transplant; WHO/IARC Global Cancer Observatory-GLOBOCAN 2022; American Cancer Society, Cancers Facts and Figures 2026

SERES THERAPEUTICS

Infections in allo-HCT are costly; Merck viral prophylaxis drug provides precedent on commercial opportunity in medically vulnerable patients

Infections in allo-HCT result in significant incremental costs with longer hospital stays, more readmissions, and increased ICU utilization

US
- Allo-HCT procedure: ~$400K year 1 per patient cost
- Transplant-related complications (e.g., infections) raise cost by ~$242K
- Prevymis cost: ~$30K; returned ICER $60K/QALY

EU
- Allo-HCT procedure: ~$95K for transplant and ~$260K to $325K for year preceding plus 2 years following procedure
- Prevymis cost: $30K-$33K for 92 days (publicly available data from Germany, France, Italy, Spain)
- ICER in line with cost-effective thresholds in high income EU countries

SER-155 targets prevention of bloodstream infections from bacterial pathogens that can lead to mortality

Prevymis, a Merck product approved by FDA in 2017 and EMA in 2018, is experiencing broad use for CMV prophylaxis (viral infection) in allo-HCT recipients

PREVYMIS® (letermovir)
240 mg, 480 mg tablets
Injection 20 mg/mL

$978M 2025 WW sales (~25% growth over '24)

- Reduces CMV infection in allo-HCT recipients
- Lowers mortality rate

Sources: CMS.gov; Broder et al, 2017 *Am Drug Health Benefits*; Perales et al, 2017 *Biol Blood Marrow Transplant*; Merck SEC filings
Cost of infections in 2015 dollars estimated at $177K by Perales, et.al. and inflated to 2025 costs (usinflationcalculator.com)

SERES THERAPEUTICS™

Value capture: highly concentrated prescriber universe enables lean commercial model

Concentrated prescriber universe

- 185 US centers performed an allo-HCT in 2016-2020
- **~80% of US transplants in 70 centers**
- Similar concentration in most major European countries

Strong familiarity with SER-155 clinical program

- Many **key centers were Ph1b trial sites**; plan to add more for future trials

Memorial Sloan Kettering Cancer Center
Massachusetts General Hospital Cancer Center
Mayo Clinic
Fred Hutch Cures Start Here
The University of Chicago Medicine
City of Hope


SERES THERAPEUTICS

SER-428 ICU BSI: Formulation to enable liquid oral dosing to expand prevention of infections in intubated and other patients unable to swallow capsules


Preclinical

Liquid oral dosing of SER-428 decolonizes key pathogens that colonize the GI tract and are associated with infections and poor outcomes

Enterococcus faecium decolonization



Klebsiella pneumoniae decolonization



- SER-428 is designed to be functionally similar to SER-155
- SER-428 is the first liquid formulation developed for oral and enteral feeding tube delivery of live biotherapeutics
- Program supported in part by CARB-X

Opportunity

Expand prevention of bloodstream and antimicrobial resistant infections to patients at high infection risk & unable to swallow capsules

- Up to 1M sepsis patients in US admitted to hospitals with over half requiring ICU admission; most patients admitted to ICU with a known or suspected infection and receive broad-spectrum antibiotics
- Infections in the ICU are consequential; infection is leading cause of death for patients admitted to the ICU with sepsis; 40% all cause mortality for patients admitted to ICU who acquire BSI (including those treated for sepsis)
- Each BSI event can lead to 15 to17 excess hospital days and $42,000 to $55,000 in excess hospital costs per hospital-onset (Yu et al. 2023. *Inf. Cont. & Hosp. Epi.*)


- IND submission pending –
Drug manufacture & testing completed

SERES THERAPEUTICS

SER-155
Immune Checkpoint Inhibitor-Related Enterocolitis (irEC)

An Alternative To Immunosuppression That May Preserve Checkpoint Inhibitor Therapy

Recent Topline Investigator Sponsored Study Results



SERES THERAPEUTICS

What is Immune Checkpoint Inhibitor-Related Enterocolitis (irEC)?

irEC is a serious, frequent complication of rapidly growing immune checkpoint inhibitor therapy that requires immunosuppressive treatment and often disrupts life-extending cancer treatment

- **Immune Checkpoint inhibitors (ICIs) activate and amplify the immune system to attack cancer cells and save lives.**
- **The immune activation / amplification that attacks cancer tumors can attack healthy tissues, including in the gastrointestinal tract, causing irEC.**
- **irEC can cause severe diarrhea, abdominal pain, bloody stool, inflammation, colitis and hospitalization.**
- **Up to 50% of ICI patients can experience irEC depending on type/regimen; moderate-to-Severe irEC occurs in ~25% of patients receiving ICI (Total ICI patients in the US in 2026 estimated at ~300k and ~3M worldwide).**
- **Current standard of care treats Grade 2 or higher irEC requires halting life-extending cancer therapy and treatment with immunosuppressive systemic corticosteroids which carry risk of negative side**



Sources: Abu-Sbeih et al, Journal for ImmunoTherapy of Cancer, 2019; Braun et al, Trends in Cancer, 2025
Guggenheim Securities Flash Report issued 12/16/24, ICI Market analysis 2024, Grandview Research, Inc; IQVIA Institute Global Oncology Trends 2025

SERES THERAPEUTICS™

A significant unmet need exists for new therapies that prevent or treat irEC without immunosuppression and that preserve life-extending checkpoint inhibitor therapy

- **Oral treatment that prevents or resolves irEC without systemic immunosuppression and without a negative impact on immune checkpoint inhibitor therapy**
- **Enables patients to continue life-extending immune checkpoint inhibitor therapy**
- **Addresses the underlying gastrointestinal mucosal epithelial barrier dysfunction and inflammation associated with immune checkpoint inhibitor induced irEC**

SER-155, an investigational live biotherapeutic, can *uniquely address the upstream drivers* of mucosal epithelial barrier dysfunction and inflammation *without systemic immunosuppression*

--

Potential to address unmet needs and limitations of current standard of care

SERES THERAPEUTICS

Top-Line Results Summary: SER-155 resulted in immunosuppressive-free clinical response with mechanistic biomarker data supporting efficacy outcomes

Memorial Sloan Kettering Cancer Center (MSK) investigator sponsored trial in cancer patients with immune checkpoint inhibitor-related enterocolitis (irEC; n=15)

Efficacy	**80% Immunosuppressive-free clinical response at Day 15 (primary endpoint)**
Safety	**Well-tolerated with No Drug related Serious Adverse Events (SAEs) identified**
Drug Pharmacology	**Improved GI mucosal epithelial barrier and reduced inflammation; clinical translation of SER-155's unique mechanisms of action in additional patient population**

SER-155 has the potential to become a critical component of cancer care

—

Reduce toxic side effects, preserve anti-tumor immunity, and enable patients to continue ICI therapy

SERES THERAPEUTICS

MSK initiated trial to evaluate safety and efficacy of SER-155, an investigational biotherapeutic optimized to specifically target the type of damage caused by ICIs

Memorial Sloan Kettering Cancer Center (MSK)
Trial Summary -- NCT06801067

Grade 2-3 irEC	• 15 participants who had not yet received immunosuppressive therapy (corticosteroids and/or biologics) for irEC • All participants had prior ICI treatment
Treatment Phase	• 1st line treatment for irEC • Oral and convenient: 2 days vancomycin conditioning followed by 12 days SER-155 (2 capsules taken once daily)
Clinical Response Assessment	• Immunosuppressive-free response in diarrhea (primary symptom of irEC) at Study Day 15 • Immunosuppressive-free response at Study Day 43 • Safety through 180 days
Drug Pharmacology	• SER-155 strain GI colonization; i.e., engraftment (PK) • Mucosal epithelial barrier integrity (GI biomarker) • Anti-inflammatory (GI & systemic biomarkers)

SERES THERAPEUTICS

SER-155 efficacy response occurred in a cancer patient population representative of current clinical practice, spanned multiple ICI and cancer types

Profile of 15 participants enrolled



Multiple cancer types

- Majority with stage 3-4

Multiple ICI types used on study:

- PD-1 inhibitors (Keytruda, Opdivo, Zynz), PD-L1 inhibitors (Imfinzi, Bavencio), CTLA-4 inhibitors (Yervoy, Imjudo), LAG-3 inhibitors (Opdualag), and combinations thereof
- All ICIs include irEC as an adverse reaction in their labels

irEC with Grade 2-3 diarrhea

- 60% of participants with Grade 3

Excellent SER-155 dosing compliance: >99%

93% participants with ICI cancer therapy interrupted at entry

SERES THERAPEUTICS™

Immune checkpoint inhibitor-related enterocolitis (irEC) is a significant side effect which can cause interruption of ICI cancer therapy and use of immunosuppressives

irEC increasing severity; *patient population is substantial and growing*

Moderate-to-Severe Population


	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5
Grade Diarrhea	Increase of <4 stools/day over baseline	Increase of 4-6 stools/day over baseline, trouble managing 'day-to-day' tasks	Increase of ≥7 stools/day over baseline; limiting self-care	Life-threatening	Death
Treatment Guidelines	Symptomatic care (i.e. loperamide) and continue ICI	• **Halt ICI therapy** • **Initiate systemic corticosteroids**		• **Halt ICI therapy** • **Initiate high dose systemic corticosteroids & biologics**	

irEC patients can experience severe diarrhea, abdominal pain, bloody stool, inflammation, colitis and hospitalization

SERES THERAPEUTICS

SER-155 Top Line Efficacy: 80% of participants achieved immunosuppressive-free response at Day 15, with 33% of participants achieving complete clinical remission

Day 15 Immunosuppressive-Free Response (Primary Endpoint; n=15)



- **Speed of Response**: 11 of 12 responders were improving by Day 8
- **Magnitude of Response**: 8 of 12 responders improved ≥ 2 grades by Day 15

Response: diarrhea decrease by one or more Grades
Remission: Grade 0 (no diarrhea)

SERES THERAPEUTICS

At Day 43, patients with a primary endpoint response at Day 15, had same grade or better

- **The 12 of 15 participants who achieved Grade 0 or Grade 1 without immunosuppressives at Day 15 following SER-155 dosing achieved the same grade or better at Day 43**
  - **Secondary Endpoint: 5 of 15 participants maintained immunosuppressive-free response (2 in remission at Grade 0; 3 at Grade 1)**
  - 7 of 15 maintained response but received non-systemically acting, gastrointestinal-targeted immunosuppressives for mild residual or moderate recurrent symptoms

Response = diarrhea decrease by ≥ 1 Grade; Remission = Grade 0 (no diarrhea)

SERES THERAPEUTICS

SER-155 Safety through Day 43: Generally well-tolerated with no treatment-related severe adverse events (SAEs)

Treatment-Emergent Adverse Events (TEAEs)



- Majority of participants (73.3%) experienced a TEAE, most mild to moderate
- Most common: diarrhea (26.7%), though diarrhea is the primary symptom associated with irEC
- 4 events were assessed by investigator as possibly related to both vancomycin and SER-155, all moderate in severity and all resolved
- No participants experienced a TEAE leading to treatment or study discontinuation

Serious Adverse Events (SAEs)



- 2 of 15 (13.3%) participants experienced an SAE: none assessed as related to SER-155 (no SUSARs)
  - Most common SAE SOCs: Gastrointestinal disorders (1); Cardiac disorders (1)
  - No deaths through Day 43; 1 death* after Day 180, considered not related to SER-155

Adverse Events of Special Interest (AESIs)



- No drug-related AESIs^
- No SER-155 species were identified in culture from any participant

* One participant had a fatal cardiac arrest, assessed as unrelated to SER-155, before they could complete their final study follow up visit.

^ One participant had an AESI (BSI) at Day 136, assessed as unrelated to SER-155

SERES THERAPEUTICS

Pharmacology: Biomarkers support SER-155 repaired mucosal epithelial barrier & reduced GI inflammation consistent with drug's design & clinical results

Pharmacokinetics

SER-155 strains colonized participants' GI tracts, i.e., engrafted, with the majority of strains observed across the study participants with kinetics, magnitude, and durability **comparable to that observed in prior Seres clinical studies**

Pharmacodynamics

Participants show high levels of gastrointestinal (GI) inflammation with a subset also showing evidence of epithelial barrier damage prior to treatment

Biomarkers of GI inflammation (fecal calprotectin) and epithelial barrier damage (fecal albumin) were elevated in participants indicating **epithelial barrier disruption and high gut inflammation at baseline** with concordant reductions after SER-155 dosing with **significant ($p < 0.05$) reductions in both measures achieved by Day 43**

Combined with clinical response rates, consistent directional improvement across both measures indicates an encouraging treatment effect on immune checkpoint inhibitor induced irEC disease activity

SERES THERAPEUTICS

SER-155 irEC Path Forward: Planning FDA engagement to discuss clinical development program for prophylaxis of irEC

Advancing the irEC Prophylaxis Program

- Prevention approach addresses unmet medical need and aims to keep patients on immune checkpoint inhibitors (ICI) therapy and avoid immunosuppressive irEC treatments
- Efficient clinical development path (cost/timeline to approval)
- Enrollment risk enhancement approach for CTLA-4 containing regimens (highest irEC risk) while still enrolling all ICI types and regimens; potential for broad ICI reach
- Prophylactic dosing optimization expected to be included in FDA engagement strategy

Unmet medical need with strong economics

- **Primary and Secondary KOL and market research results confirmed that prophylaxis approach of SER-155 in irEC represents a multi-billion dollar opportunity**
  - Physicians' favorable adoption rates (>75%) based on SER-155 target product profile (TPP)
  - Biologics and Prevymis provide reasonable pricing analogues
- There is currently no SOC for prophylaxis of irEC
- irEC is a clinically significant adverse reaction and present in the approved labels of all ICI treatments, and significant market growth factors are present

SERES THERAPEUTICS

SER-155 irEC study results are clinically meaningful and represent an additional valuable oncology indication

Immune checkpoint inhibitors have revolutionized cancer treatment and represent a sizable market

11 Drug Approvals
across 20+ solid tumor types (e.g., lung, melanoma, colorectal, etc.)

Well over $50B
[KEYTRUDA, OPDIVO, YERVOY, IMFINZI, *others*]

~15% projected CAGR
through early 2030's

Immune checkpoint inhibitors can cause irEC that can interrupt life-saving cancer treatment

Up to 50% of ICI patients can experience irEC

Moderate-to-Severe irEC occurs in ~25% of ICI treated patients and disrupts cancer treatment

Unmet clinical needs
irEC prophylaxis to prevent disruption of cancer therapy and non-immunosuppressive treatment to avoid negative impacts on treatment

SER-155 has the potential to become a critical component of cancer care across multiple indications

Achieved 80% immunosuppressive-free response & well-tolerated


Potential utility of SER-155 to address unmet needs in multiple oncology areas

Pharmacology data support broad potential of Seres novel live biotherapeutics

SERES THERAPEUTICS


SER-603
Inflammatory Bowel Disease (IBD)

Targeting inflammatory drivers of IBD that current standards of care cannot



SERES THERAPEUTICS

Key challenges in IBD suggest new solutions are needed




- **Efficacy ceiling** experienced by many patients due to non-response or poor durability of response (see figure)
- **Safety concerns** limit the potential for combining advanced therapies that are immunosuppressive
- **Current therapies don't directly target the mucosal epithelial barrier**, a critical target for limiting inflammation
- **Patient heterogeneity in IBD patients is a core challenge** and key reason many drugs don't work or lack durability.
- **Disrupted gut microbiome function** is a major driver of IBD heterogeneity, pathogenesis, and nonresponse to advanced therapies


SER-603 offers an effective, safe approach to address these gaps

SERES THERAPEUTICS

Biomarker Validation: Identified bacterial features can predict response to therapy in clinical datasets

Wang et. al. 2025 *- significant impact of microbiome on ustekinumab efficacy*





Non-Remission
Remission


50% of CD patients remit after ustekinumab in each cohort

Seres Biomarker can **predict response to therapy**

~70% of patients
Biomarker (-)
Non-inflammatory microbiome


~30% of patients
Biomarker (+)
Inflammatory microbiome

Selection of Biomarker (-) patients increases remission after ustekinumab



68% of Seres Biomarker (-) patients experience remission suggesting patients that do NOT have an inflammatory microbiome are more likely to respond to ustekinumab.


Selection of Biomarker (+) patients identifies patients for combination therapy




8% of Seres biomarker (+) patients experience remission, suggesting patients that have an inflammatory microbiome are very unlikely to respond to Ustekinumab, and may be candidates for combination therapy.

SERES THERAPEUTICS


Monotherapy Proof of Concept: SER-603 addresses microbiome-driven inflammation in preclinical disease models of IBD



SER-603 intervention reduces fecal lipocalin from inflammatory microbiome



SER-603 intervention reduces Th1 and Th17 CD4+ T cells




SERES THERAPEUTICS


Combination Therapy Proof of Concept: SER-603 increases the efficacy of anti-TNFα therapy in a preclinical model of microbiome-driven inflammation



SER-603 + anti-TNFα is superior to anti-TNFα alone in reducing lipocalin




SER-603 + anti-TNFα is superior to anti-TNFα alone in reducing Th1 and Th17 CD4+ T cells



SERES THERAPEUTICS

SER-603 holds the potential to address challenge of inadequate response in IBD patients as well as benefit patients earlier



Well-tolerated safety profile and oral delivery creates potential for SER-603 to target mild-moderate patients as **Monotherapy or add-on to 5-ASA**

~30% of UC patients are either "smoldering", (on 5-ASA and suffering silently), supplementing 5-ASA treatment with corticosteroids, or switching to immunomodulators and would be appropriate for an LBP instead


Novel and complementary mechanism of action for **combo with advanced therapies** to convert partial or non-responders to remitters and expand durability of response without increased safety concerns

Many advanced therapies exhibit an efficacy ceiling and lack durability of response, instead of switching to another biologic, adding an LBP has the potential improve and extend efficacy

"The biologics are a big step up for a lot of moderate patients, it would be nice to have a safe oral treatment that fills the space before a biologic" - UC KOL

SERES THERAPEUTICS

Seres continues on successful journey to lead on delivering on the therapeutic potential of live biotherapeutics (LBP)



The NEW ENGLAND JOURNAL of MEDICINE
SER-109 (VOWST) Phase 3 efficacy

JAMA RESEARCH LETTER
SER-109 (VOWST) Phase 3 durability

Clinical Infectious Diseases
MAJOR ARTICLE
Reduced antibiotic resistance gene carriage


nature medicine
VOWST mechanism of action
SER-155 Phase 1b allo-HCT efficacy

nature microbiology
SER-155 mechanism of action (in review)

Seres has delivered an approved drug and additional clinical candidates in a novel therapeutic modality that address diseases in an innovative way

SERES THERAPEUTICS™

THANK YOU



SERES THERAPEUTICS